DK3149042T3 - PD-L1-antistoffer og anvendelser deraf - Google Patents

PD-L1-antistoffer og anvendelser deraf Download PDF

Info

Publication number
DK3149042T3
DK3149042T3 DK15725043T DK15725043T DK3149042T3 DK 3149042 T3 DK3149042 T3 DK 3149042T3 DK 15725043 T DK15725043 T DK 15725043T DK 15725043 T DK15725043 T DK 15725043T DK 3149042 T3 DK3149042 T3 DK 3149042T3
Authority
DK
Denmark
Prior art keywords
antibodies
Prior art date
Application number
DK15725043T
Other languages
Danish (da)
English (en)
Inventor
Yifei Zhu
Zhiming Liao
Fernando Couto
Original Assignee
Spring Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bioscience Corp filed Critical Spring Bioscience Corp
Application granted granted Critical
Publication of DK3149042T3 publication Critical patent/DK3149042T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK15725043T 2014-05-29 2015-05-29 PD-L1-antistoffer og anvendelser deraf DK3149042T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004572P 2014-05-29 2014-05-29
US201462069420P 2014-10-28 2014-10-28
PCT/EP2015/061921 WO2015181342A1 (en) 2014-05-29 2015-05-29 Pd-l1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DK3149042T3 true DK3149042T3 (da) 2019-11-04

Family

ID=53268817

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15725043T DK3149042T3 (da) 2014-05-29 2015-05-29 PD-L1-antistoffer og anvendelser deraf

Country Status (8)

Country Link
US (2) US9885721B2 (enExample)
EP (1) EP3149042B1 (enExample)
JP (1) JP6666905B2 (enExample)
AU (1) AU2015265870B2 (enExample)
CA (1) CA2947932C (enExample)
DK (1) DK3149042T3 (enExample)
ES (1) ES2753360T3 (enExample)
WO (1) WO2015181342A1 (enExample)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
KR20250091304A (ko) 2013-03-15 2025-06-20 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
ES2753360T3 (es) 2014-05-29 2020-04-08 Spring Bioscience Corp Anticuerpos contra PD-L1 y usos de los mismos
BR112017000497B1 (pt) * 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EP3254110B1 (en) * 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
CN111349118B (zh) 2015-05-18 2023-08-22 住友制药肿瘤公司 具有增加的生物利用度的阿伏西地前药
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CN105717298A (zh) * 2016-01-29 2016-06-29 浙江数问生物技术有限公司 Pd-l1免疫组化试剂盒
WO2017148424A1 (zh) 2016-03-04 2017-09-08 四川科伦博泰生物医药股份有限公司 一种pdl-1抗体、其药物组合物及其用途
PL3455257T3 (pl) 2016-05-09 2022-01-17 Igm Biosciences Inc. Przeciwciała anty-pd-l1
JP7241352B2 (ja) 2016-05-17 2023-03-17 ジーンセントリック セラピューティクス， インコーポレイテッド 肺扁平上皮癌のサブタイピングのための方法
CA3024747A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
EP3464369A1 (en) * 2016-06-03 2019-04-10 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN107488229B (zh) * 2016-06-13 2020-11-17 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
EP3497128A2 (en) 2016-08-09 2019-06-19 Kymab Limited Anti-icos antibodies
ES3049875T3 (en) 2016-09-20 2025-12-18 Merck Patent Gmbh Diagnostic anti-pd-l1 antibody and use thereof
TW202436356A (zh) 2016-10-11 2024-09-16 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
AU2017378226A1 (en) 2016-12-14 2019-06-20 Janssen Biotech, Inc. CD8A-binding fibronectin type III domains
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
EP3568412A2 (en) 2017-01-13 2019-11-20 Agenus Inc. T cell receptors that bind to ny-eso-1 and methods of use thereof
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
KR20200019865A (ko) 2017-06-22 2020-02-25 노파르티스 아게 암 치료에 사용하기 위한 il-1베타 결합 항체
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3645048A4 (en) * 2017-06-25 2021-06-16 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
CN111163798A (zh) 2017-07-20 2020-05-15 诺华股份有限公司 用于抗lag-3抗体的给药方案及其用途
KR20200052327A (ko) 2017-09-04 2020-05-14 아게누스 인코포레이티드 혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
JP2021503077A (ja) 2017-11-09 2021-02-04 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 細胞外小胞タンパク質、ならびに癌診断、療法に対する応答予測、および治療をするためのそれらの使用
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
KR20250151605A (ko) 2018-06-01 2025-10-21 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
EP3818085A4 (en) 2018-06-01 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS
BR122022012697B1 (pt) 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN109232740B (zh) * 2018-08-20 2022-05-10 中国科学院微生物研究所 一种抗pd-l1抗体及其在抗肿瘤治疗中的应用
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
BR112021008795A2 (pt) 2018-11-13 2021-08-31 Compass Therapeutics Llc Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos
MX2021006544A (es) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
AU2019406840A1 (en) 2018-12-21 2021-06-03 Novartis Ag Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
MX2021007271A (es) 2018-12-21 2021-07-15 Onxeo Nuevas moleculas de acido nucleico conjugado y sus usos.
US20220056123A1 (en) 2018-12-21 2022-02-24 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
KR20210121047A (ko) * 2018-12-27 2021-10-07 기가젠, 인코포레이티드 항-pd-l1 결합 단백질 및 이의 사용 방법
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
CN114302878A (zh) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 酪氨酸激酶非受体1(tnk1)抑制剂及其用途
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AU2020335928A1 (en) 2019-08-30 2022-02-17 Agenus Inc. Anti-CD96 antibodies and methods of use thereof
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
BR112022007376A2 (pt) 2019-10-21 2022-07-05 Novartis Ag Terapias de combinação com venetoclax e inibidores de tim-3
AU2020370832A1 (en) 2019-10-21 2022-05-19 Novartis Ag TIM-3 inhibitors and uses thereof
US20230000864A1 (en) 2019-11-22 2023-01-05 Sumitomo Pharma Oncology, Inc. Solid dose pharmaceutical composition
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
MX2022008763A (es) 2020-01-17 2022-07-27 Novartis Ag Combinacion que comprende un inhibidor de tim-3 y un agente hipometilante para usarse en el tratamiento del sindrome mielodisplasico o leucemia mielomonocitica cronica.
EP4097234A1 (en) 2020-01-28 2022-12-07 Université de Strasbourg Antisense oligonucleotide targeting linc00518 for treating melanoma
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20250262293A1 (en) 2020-07-07 2025-08-21 BioNTech SE Therapeutic rna for hpv-positive cancer
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CN116194475A (zh) 2020-08-31 2023-05-30 Sab有限责任公司 对冠状病毒蛋白具有特异性的有蹄类动物源性多克隆免疫球蛋白和其用途
CA3197069A1 (en) * 2020-10-13 2022-04-21 Immunovaccine Technologies Inc. Methods of treating diffuse large b-cell lymphoma
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
EP4244247A4 (en) * 2020-11-13 2024-12-18 Sab, Llc HUPTA-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR PD-L1 AND USES THEREOF
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
EP4308935A1 (en) 2021-03-18 2024-01-24 Novartis AG Biomarkers for cancer and methods of use thereof
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
US20240294926A1 (en) 2021-12-16 2024-09-05 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
CN119013022A (zh) 2022-03-14 2024-11-22 来凯有限公司 癌症的组合治疗
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
JP7811807B2 (ja) * 2022-08-29 2026-02-06 国立大学法人北海道大学 Ｐｄ－ｌ１検出用抗ｐｄ－ｌ１抗体
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
EP4626446A1 (en) 2022-12-01 2025-10-08 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
JP2026504180A (ja) 2023-01-30 2026-02-03 カイマブ・リミテッド 抗体
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
WO2024228167A1 (en) 2023-05-03 2024-11-07 Iox Therapeutics Inc. Inkt cell modulator liposomal compositions and methods of use
CN117384291B (zh) * 2023-07-28 2024-07-05 武汉爱博泰克生物科技有限公司 抗人sall4兔单克隆抗体及其制备方法和应用、多核苷酸分子、表达载体和宿主细胞
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025085404A1 (en) 2023-10-16 2025-04-24 Genentech, Inc. Diagnostic and therapeutic methods for treating lung cancer
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
CN119841957B (zh) * 2025-01-13 2025-08-05 上海领检科技有限公司 一种抗人IgE抗体及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922855A (en) 1993-12-17 1999-07-13 Oregon Health Sciences University Mammalian DNA mismatch repair genes MLH1 and PMS1
CA2307330A1 (en) 1997-10-21 1999-04-29 The University Court Of The University Of Glasgow Jmy, a co-activator for p300/cbp, nucleic acid encoding jmy and uses thereof
CA2383424C (en) 1999-08-23 2011-02-15 Gordon Freeman Novel b7-4 molecules and uses therefor
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2012211347B9 (en) 2004-07-20 2015-06-18 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2006042237A2 (en) 2004-10-06 2006-04-20 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
US7895540B2 (en) 2006-08-02 2011-02-22 Georgia Tech Research Corporation Multilayer finite difference methods for electrical modeling of packages and printed circuit boards
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
EP2482849B1 (en) 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
WO2012003476A2 (en) 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Hapten conjugates for target detection
CN102250911A (zh) 2011-05-31 2011-11-23 苏州大学 一种可溶性b7-h1定量检测试剂盒
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9846162B2 (en) 2012-05-14 2017-12-19 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
CN104936982B (zh) * 2012-08-03 2020-04-24 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
US20150071910A1 (en) 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
EP2981821B2 (en) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
JP6581982B2 (ja) 2013-07-24 2019-09-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ガレクチン−１（ｇａｌ１）を中和するための抗ｇａｌ１モノクローナル抗体およびその断片
GB201316027D0 (en) 2013-09-09 2013-10-23 Almac Diagnostics Ltd Molecular diagnostic test for oesophageal cancer
GB201316024D0 (en) 2013-09-09 2013-10-23 Almac Diagnostics Ltd Molecular diagnostic test for lung cancer
WO2015038538A1 (en) 2013-09-10 2015-03-19 Medimmune, Llc Compositions and methods for treating sepsis
PL3043816T3 (pl) 2013-09-11 2020-03-31 Medimmune Limited Przeciwciała anty-b7-h1 do leczenia nowotworów
WO2015061668A1 (en) * 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
US10241115B2 (en) 2013-12-10 2019-03-26 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
WO2015124703A1 (en) 2014-02-24 2015-08-27 Ventana Medical Systems, Inc. Quinone methide analog signal amplification
ES2753360T3 (es) 2014-05-29 2020-04-08 Spring Bioscience Corp Anticuerpos contra PD-L1 y usos de los mismos
AU2015265871B2 (en) 2014-05-30 2020-01-23 Ventana Medical Systems, Inc. Multiplex assay for improved scoring of tumor tissues stained for PD-L1

Also Published As

Publication number Publication date
US20180196055A1 (en) 2018-07-12
CA2947932C (en) 2021-03-30
WO2015181342A1 (en) 2015-12-03
CA2947932A1 (en) 2015-12-03
AU2015265870B2 (en) 2020-07-09
US20150346208A1 (en) 2015-12-03
EP3149042B1 (en) 2019-08-28
JP6666905B2 (ja) 2020-03-18
AU2015265870A1 (en) 2016-10-13
EP3149042A1 (en) 2017-04-05
US9885721B2 (en) 2018-02-06
US10775383B2 (en) 2020-09-15
JP2017518366A (ja) 2017-07-06
ES2753360T3 (es) 2020-04-08

Similar Documents

Publication Publication Date Title
IL304772A (en) Antibodies, uses and methods
IL283965A (en) Antibodies against cd73 and uses thereof
DK3149042T3 (da) PD-L1-antistoffer og anvendelser deraf
IL263834A (en) Anti-pd-l1 antibodies
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3922645T3 (da) Anti-pro/latent-myostatin-antistoffer og anvendelse heraf
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
HUE045216T2 (hu) Anti-CD79B antitestek és alkalmazási eljárások
IL251963A0 (en) Anti-pd-1 antibodies
PL3653221T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
ME03558B (me) Molekuli anti-lag-3 antiтela i njihove upotrebe
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
DK3116911T3 (da) Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
IL248781B (en) Pesticidal compositions and related methods
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3402821T5 (da) Psma-bindende antistof og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
IL291164A (en) Anti-nme antibody
EP3835319C0 (en) Humanized Anti-ACTH Antibodies and Their Use
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
IL282201B (en) Anti-tenascin c antibodies and uses thereof
DK3110447T3 (da) Anti-EGFR-antistof og anvendelser heraf